ArticleTranslational cancer research2025
An efficient epithelial-mesenchymal transition-related gene signature for predicting the survival of patients with lung adenocarcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelial-mesenchymal transition (EMT) plays an important role in the pathogenesis of lung adenocarcinoma (LUAD). In this study, we aimed to construct a prognostic signature based on EMT that could predict the prognosis of patients with LUAD. Methods: The messenger RNA (mRNA) expression profiles and the clinical data were downloaded from The Cancer Genome Atlas (TCGA) as the training set while data from the Gene Expression Omnibus (GEO) served as the validation set. Differentially expressed EMT-related genes (EMTGs) were identified from the training dataset. Univariate and multivariate Cox regression analyses were employed to develop a gene signature from the EMTGs to predict overall survival (OS) time. The prediction performance of the signature was tested using the time-dependent receiver operating characteristic (ROC) curve. The signature was verified in the TCGA dataset and the external dataset, GSE30219. A corresponding nomogram was also constructed to predict the prognosis of patients with LUAD. The expression of the prognostic genes at the protein level was investigated in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset. Gene set enrichment analysis was conducted to reveal the biological pathways associated with the high-risk group and the low-risk group. Results: A set of 79 differentially expressed EMTGs were identified. An EMT-related signature was constructed which classified patients with LUAD into two subgroups based on the median risk score. In the ROC curve analysis, the prognostic signature had a moderate discrimination accuracy for the 1-, 3-, and 5-year survival rate with areas under the curve (AUCs) of 0.732, 0.675, 0.702 in TCGA training set, respectively and 0.813, 0.672, 0.706 in the GSE30219 validation set, respectively. The established nomogram effectively predicted the OS of patients with LUAD. Conclusions: The novel EMT-related signature established in this study is a robust and independent prognostic indicator for patients with LUAD. This signature is expected to improve the personalized management of patients with LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.